National Center for Health Statistics (NCHS), ICD-10 Coordination and Maintenance (C&M) Committee Meeting, 5882-5883 [2023-01801]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 88, Number 19 (Monday, January 30, 2023)]
[Notices]
[Pages 5882-5883]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01801]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


National Center for Health Statistics (NCHS), ICD-10 Coordination 
and Maintenance (C&M) Committee Meeting

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The CDC, National Center for Health Statistics (NCHS), 
Classifications and Public Health Data Standards Staff, announces the 
following meeting of the ICD-10 Coordination and Maintenance (C&M) 
Committee. This meeting is open to the public, limited only by the 
number of audio lines available. Online registration is required.

DATES: The meeting will be held on March 7, 2023, from 9 a.m. to 5 
p.m., EST, and March 8, 2023, from 9 a.m. to 5 p.m., EST.

ADDRESSES: This is a virtual meeting. Register in advance at https://cms.zoomgov.com/webinar/register/WN__piUmNYaRjmkcYczb3ePIQ. After 
registering, you will receive a confirmation email containing 
information about joining the meeting. Further information will be 
provided on each of the respective web pages when it becomes available. 
For the Centers for Disease Control and Prevention, National Center for 
Health Statistics: https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm. For the Centers for Medicare & Medicaid 
Services, Department of Health and Human Services: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.

FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Systems 
Specialist, National Center for Health Statistics, CDC, 3311 Toledo 
Road, Hyattsville, Maryland 20782-2064; Telephone: (301) 458-4454; 
Email: [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is 
a public forum for the presentation of proposed modifications to the 
International Classification of Diseases, Tenth Revision, Clinical 
Modification (CM) and ICD-10 Procedure Coding System (PCS).
    Matters To Be Considered: The tentative agenda will include 
discussions on the ICD-10-CM and ICD-10-PCS topics listed below. Agenda 
items are subject to change as priorities dictate. Please refer to the 
posted agenda for updates one month prior to the meeting.

ICD-10-PCS Topics

1. Administration of Elranatamab *
2. Administration of Epcoritamab *
3. Administration of Glofitamab *
4. Administration of Pafolacianine *
5. Administration of Posoleucel **
6. Administration of Quizartinib *
7. Administration of Rezafungin *
8. Administration of SER-109 *
9. Administration of Sulbactam-Durlobactam *
10. Implantation of Bioprosthetic Femoral Venous Valves
11. Rapid Antimicrobial Susceptibility Testing of Blood Cultures *
12. Dual-Chamber Leadless Cardiac Pacemaker *
13. Percutaneous Femoral-Popliteal Artery Bypass *
14. Insertion of Lengthening Device for Esophageal Atresia
15. Implantation of Extraluminal Saphenous Vein Graft Support Device 
During Coronary Artery Bypass Graft (CABG) *
16. Short-term External Heart Assist with Graft
17. Ultrasound Ablation of Renal Sympathetic Nerves *
18. Computer-aided Detection of Heart Failure in Echocardiography *
19. Percutaneous Mechanical Circulatory Support
20. Monitoring of Intracranial Electrical Activity for Status 
Epilepticus *
21. Monitoring of Intracranial Electrical Activity for Delirium *
22. Rapid Antimicrobial Susceptibility Testing System for Blood and 
Body Fluid Cultures *
23. Percutaneous Hepatic Perfusion with Administration of Melphalan 
Hydrochloride **
24. Insertion of Muscle Compartment Pressure Monitor *
25. Insertion of Tibial Extension Implant During Total Knee 
Arthroplasty *
26. Talar Replacement of Ankle *
27. Ankle Fusion with Truss Implant *

[[Page 5883]]

28. Computer-aided Triage and Notification for Measurement of 
Intracranial Vessel Flow *
29. Extravascular Implantable Defibrillator Leads

* Requestor has submitted a new technology add-on payment (NTAP) 
application for FY 2024.
** Requestor intends to submit an NTAP application for FY 2025 
consideration.
    Presentations for procedure code requests are conducted by both the 
requestor and the Centers for Medicare & Medicaid Services (CMS) during 
the C&M Committee meeting. Discussion from the requestor generally 
focuses on the clinical issues for the procedure or technology, 
followed by the proposed coding options from a CMS analyst. Topics 
presented may also include requests for new procedure codes that relate 
to a new technology add-on payment (NTAP) policy request.
    CMS has modified the approach for presenting the new NTAP-related 
ICD-10-PCS procedure code requests that involve the administration of a 
therapeutic agent. For the March 7-8, 2023, ICD-10 C&M Committee 
meeting, consistent with the requirements of section 1886(d)(5)(K)(iii) 
of the Social Security Act, applicants submitted requests to create a 
unique procedure code to describe the administration of a therapeutic 
agent, such as the option to create a new code in Section X within the 
ICD-10-PCS procedure code classification. CMS will initially display 
only those meeting materials associated with the NTAP-related ICD-10-
PCS procedure code requests that involve the administration of a 
therapeutic agent on the CMS website in February 2023 at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.
    The nine NTAP-related ICD-10-PCS procedure code requests that 
involve the administration of a therapeutic agent are:

1. Administration of Elranatamab *
2. Administration of Epcoritamab *
3. Administration of Glofitamab *
4. Administration of Pafolacianine *
5. Administration of Posoleucel **
6. Administration of Quizartinib *
7. Administration of Rezafungin *
8. Administration of SER-109 *
9. Administration of Sulbactam-Durlobactam *

    These topics will not be presented during the March 7-8, 2023, 
meeting. CMS will solicit public comments regarding any clinical 
questions or coding options included for these nine procedure code 
topics in advance of the meeting continuing through the end of the 
respective public comment periods. Members of the public should send 
any questions or comments to the CMS mailbox at: 
[email protected].
    CMS intends to post a question-and-answer document in advance of 
the meeting to address any clinical or coding questions that members of 
the public may have submitted. Following the conclusion of the meeting, 
CMS will post an updated question-and-answer document to address any 
additional clinical or coding questions that members of the public may 
have submitted during the meeting that CMS was not able to address or 
that were submitted after the meeting.
    The NTAP-related ICD-10-PCS procedure code requests that do not 
involve the administration of a therapeutic agent and all non-NTAP-
related procedure code requests will continue to be presented during 
the virtual meeting on March 7, 2023, consistent with the standard 
meeting process.
    CMS will make all meeting materials and related documents available 
at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. Any inquiries related to the procedure code topics scheduled 
for the March 7-8, 2023, ICD-10 C&M Committee meeting that are under 
consideration for October 1, 2023, implementation should be sent to the 
CMS mailbox at: [email protected].

ICD-10-CM Topics

1. Anal Fistula
2. Bicuspid Aortic Valve
3. Epileptic Seizures Related to External Causes, Intractable
4. Eating Disorders
5. Flank Anatomical Specificity
6. Gulf War Illness
7. Lymphoma in Remission
8. Nonionizing Radiation Sensitivity and Toxicity (NIRST)
9. Personal History of Colonic Polyps
10. Sepsis Aftercare
11. Addenda

    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-01801 Filed 1-27-23; 8:45 am]
BILLING CODE 4163-18-P